Wong TY, Mwamburi M, Klein R, et al
Fair enough, but thats only half of the story, and heres the other half: There are around nine research studies that Medifast has been a part of, the follow up time was never longer than 12 months, except for in one case, when follow up was done after 86 weeks
Nutritional status is another consideration
By providing a common framework, the guidance helps shift the conversation from whether NAMs can be considered to how they can be appropriately applied to answer specific regulatory questions, e.g., derisking treatmentrelated findings observed in animal studies with humanrelevant mechanistic data
After all, tirzepatide was originally approved as Mounjaro for managing T2D
Understanding these physiological changes helps explain why food quality not just quantity becomes critical during GLP-1 therapy